<DOC>
	<DOC>NCT00699335</DOC>
	<brief_summary>The aim of the study was to evaluate the efficacy and safety of Matrifen® in patients with severe and chronic pain who could only be sufficiently treated with opioid analgetics (WHO class 3).</brief_summary>
	<brief_title>Matrifen® for Therapy of Severe Chronic Pain®</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Main inclusion criteria: Outpatients with severe, chronic pain Main exclusion criteria: Hypersensitivity to fentanyl Coadministration of monoamineoxidaseinhibitors Pregnancy Respiratory depression Chronic obstructive pulmonary disease (COPD) Drug abuse Impairment of CNS functions Other criteria as defined in the Summary of Product Characteristics (Chapter 4.3)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>pain</keyword>
	<keyword>fentanyl</keyword>
	<keyword>transdermal patch</keyword>
</DOC>